Kliniken Ostalb gemeinnuetzige kommunale Anstalt des oeffentlichen Rechts — Clinical Trial Site

38 Registered trials

16 Currently recruiting

Organisation

Kliniken Ostalb gemeinnuetzige kommunale Anstalt des oeffentlichen Rechts

Location

Mutlangen, Germany

Identifier

ORG-100041965

Address

Wetzgauer Strasse 85, 73557, Germany

Departments

-
#5006:Zentrum Für Innere Medizin
Center for Internal Medicine
Frauenklinik
Hämatologie und Onkologie
Hämatologie und Onkologie Mutlangen
Hematology and oncology
Innere Medizin
Internal Medicine
Internal Medicine and Hematology
Internal medicine, division of hematology/oncology
Medizinische Klinik I
not applicable
Oncology Center
Onkologisches Zentrum
Schwerpunkt Hämatologie / Internistische Onkologie
Standort Stauferklinikum Schwäbisch Gmünd
Standort Stauferklinikum Schwäbisch Gmünd - Zentrum für Innere Medizin
Standort Stauferklinikum, Zentrum für Innere Medizin
Stauferklinikum Schwäbisch Gmünd
Stauferklinikum Schwäbisch Gmünd Zentrum für Innere Medizin
Zentrum fuer Innere Medizin
Zentrum für Innere Medizin
Zentrum für Innere Medizin, Hämatologie/ Onkologie
Zentrum Innere Medizin

Clinical trials at this site (38)

Search interface

Short course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined… Ended

2024-511577-29-01 intermediate and high-risk rectal cancer 5 2020-03-13
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previo… Ended

2024-511747-25-00 B-cell non-Hodgkin lymphoma (NHL) 4 2019-12-23
Copanlisib and Rituximab in Marginal Zone Lymphoma Patients - A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (COUP-1) Ended

2022-500674-34-00 Marginal Zone Lymphoma 4 2019-11-04
Efficacy of first line Bortezomib, Rituximab, Ibrutinib (B-RI) for patients with treatment naive Waldenström’s Macroglobulinemia Ended

2022-500584-12-00 Waldenström’s Macroglobulinemia 4 2019-09-11
Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagno… Ended

2023-503670-21-00 Patients with newly diagnosed AML and intermediate- or 5 2019-08-28
A Phase 3 study to see the benefit and safety of Luspatercept in comparison with Epoetin Alfa to treat anaemia due to very low, low or inter… Ended

2022-501485-22-00 Myelodysplastic syndrome (MDS) 5 2018-12-18
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treat… Ended

2024-513912-89-00 Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofi 10 2018-12-13
DANTE / FLOT8 A randomized, open-label Phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in … Ended

2024-514945-12-00 locally advanced resectable adenocarcinoma of the oesop 10 2018-09-03
Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following Autologous Stem Cel… Ended

2024-515783-31-00 Newly Diagnosed Multiple Myeloma 5 2018-08-24
HU-F-AIM - A prospective, interventional clinical study to evaluate hydroxyurea (HU) resistance in patients with polycythaemia vera who meet… Ended

2022-502338-20-00 Polycythemia vera 6 2023-07-28
A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous… Ended

2024-516300-41-00 Multiple Myeloma 5 2023-03-07
CIRCULATE Ended

2023-506715-18-00 colon cancer stage II, rectal cancer stage II 5 2019-12-04
HD21 Ended

2024-518022-33-00 Advanced Stage of Hodgkin Lymphoma 5 2016-07-15
A Study to Compare the Efficacy and Safety of a Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and … Ended

2023-504034-22-00 Chronic Lymphocytic Leukemia (CLL) 5 2014-12-18